Atea Pharmaceuticals is trading at $4.22, with a -5.38% change, as technology shares lead a sharp market-wide retreat. - Reports cite concerns about AI infrastructure spending and regulatory scrutiny as pressures on markets. - No company-specific announcement explaining the move surfaced in the search. - Atea’s next scheduled quarterly results and business update call is November 9, not a November 5 catalyst.